文献速递淋巴瘤

阿基仑赛治疗复发/难治性惰性非霍奇金淋巴瘤的三年随访分析(ZUMA-5)

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
PubMed 文献 · Blood · 2024-01-01

ZUMA-5是一项2期、多中心、单臂研究,纳入104例复发/难治性惰性非霍奇金淋巴瘤患者(包括滤泡性淋巴瘤和边缘区淋巴瘤),接受阿基仑赛输注(2×10^6个CAR T细胞/kg)。中位随访41.7个月(滤泡性淋巴瘤,n=127)和31.8个月(边缘区淋巴瘤,n=31)后,总缓解率分别为94%和77%,中位无进展生存期滤泡性淋巴瘤为40.2个月,边缘区淋巴瘤未达到,两种疾病类型的中位总生存期均未达到。

要点

  • 滤泡性淋巴瘤中位随访41.7个月,总缓解率94%,与主要分析(92%)相当。
  • 边缘区淋巴瘤中位随访31.8个月,总缓解率77%,中位无进展生存期未达到。
  • 滤泡性淋巴瘤中位无进展生存期40.2个月,两种疾病类型中位总生存期均未达到。

核心结论

  • 经过3年随访,阿基仑赛在复发/难治性惰性非霍奇金淋巴瘤患者中显示出持续持久的缓解,2年后复发极少,安全性可控。

研究设计与样本

  • 2期、多中心、单臂ZUMA-5研究,纳入104例复发/难治性惰性非霍奇金淋巴瘤患者(包括滤泡性淋巴瘤和边缘区淋巴瘤),接受白细胞分离术、淋巴细胞清除化疗后输注阿基仑赛(2×10^6个CAR T细胞/kg)。
  • 主要终点为总缓解率,本次分析由研究者在意向治疗的全部入组患者中评估。

主要发现

  • 滤泡性淋巴瘤(n=127)中位随访41.7个月,总缓解率94%;边缘区淋巴瘤(n=31)中位随访31.8个月,总缓解率77%。
  • 滤泡性淋巴瘤中位无进展生存期为40.2个月,边缘区淋巴瘤中位无进展生存期未达到。
  • 两种疾病类型的中位总生存期均未达到。
  • 先前分析后发生的≥3级关注不良事件大多出现在近期治疗的患者中。
  • 临床和药代动力学结局与近期接触苯达莫司汀和高代谢肿瘤体积呈负相关。

关键数值与推荐

  • 主要分析(中位随访17.5个月)时总缓解率为92%(完全缓解率74%)。
  • 本次分析滤泡性淋巴瘤总缓解率94%,边缘区淋巴瘤总缓解率77%。
  • 滤泡性淋巴瘤中位无进展生存期40.2个月,边缘区淋巴瘤未达到;两种疾病类型中位总生存期均未达到。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Approval was supported by the phase 2, multicenter, single-arm ZUMA-5 study of axi-cel for patients with R/R indolent non-Hodgkin lymphoma (iNHL; N = 104), including FL and marginal zone lymphoma (MZL). In the primary analysis (median follow-up, 17.5 months), the overall response rate (ORR) was 92% (complete response rate, 74%). Here, we report long-term outcomes from ZUMA-5. Eligible patients with R/R iNHL after ≥2 lines of therapy underwent leukapheresis, followed by lymphodepleting chemotherapy and axi-cel infusion (2 × 106 CAR T cells per kg). The primary end point was ORR, assessed in this analysis by investigators in all enrolled patients (intent-to-treat). After median follow-up of 41.7 months in FL (n = 127) and 31.8 months in MZL (n = 31), ORR was comparable with that of the primary analysis (FL, 94%; MZL, 77%). Median progression-free survival was 40.2 months in FL and not reached in MZL. Medians of overall survival were not reached in either disease type. Grade ≥3 adverse events of interest that occurred after the prior analyses were largely in recently treated patients. Clinical and pharmacokinetic outcomes correlated negatively with recent exposure to bendamustine and high metabolic tumor volume. After 3 years of follow-up in ZUMA-5, axi-cel demonstrated continued durable responses, with very few relapses beyond 2 years, and manageable safety in patients with R/R iNHL. The ZUMA-5 study was registered at www.clinicaltrials.gov as #NCT03105336.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Neelapu SS, Chavez JC, Sehgal AR, et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024. PMID: 37879047. doi:10.1182/blood.2023021243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。